421 Specific cephalosporin antibiotics deplete tumor PD-L1 to inhibit DNA damage sensing and sensitize to Chk1 inhibitors in vivo

por Murray, Clare, Kornepati, Anand, Padron, Alvaro, Deng, Yilun, Garcia, Myrna, Bai, Haiyan, Curiel, Tyler
Publicado 2022

4579 Distinct clinical and immunological responses to αPD-1, kαPD-L1 and αPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2...

por Garcia, Myrna G, Padron, Alvaro, Deng, Yilun, Gupta, Harshita, Kancharla, Aravind, Reyes, Ryan, Curiel, Tyler
Publicado 2020

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

por Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J
Publicado 2021

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice

por Garcia, Myrna G., Deng, Yilun, Murray, Clare, Reyes, Ryan M, Padron, Alvaro, Bai, Haiyan, Kancharla, Aravind, Gupta, Harshita, Shen-Orr, Shai, Curiel, Tyler J.
Publicado 2022

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer

por Gupta, Harshita B, Clark, Curtis A, Yuan, Bin, Sareddy, Gangadhara, Pandeswara, Srilakshmi, Padron, Alvaro S, Hurez, Vincent, Conejo-Garcia, José, Vadlamudi, Ratna, Li, Rong, Curiel, Tyler J
Publicado 2016

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents

por Murray, Clare, Galvan, Eva, Ontiveros, Carlos, Deng, Yilun, Bai, Haiyan, Padron, Alvaro Souto, Hinchee-Rodriguez, Kathryn, Garcia, Myrna G., Kornepati, Anand, Conejo-Garcia, Jose, Curiel, Tyler J.
Publicado 2022

Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

por Hurez, Vincent, Dao, Vinh, Liu, Aijie, Pandeswara, Srilakshmi, Gelfond, Jonathan, Sun, Lishi, Bergman, Molly, Orihuela, Carlos J., Galvan, Veronica, Padrón, Álvaro, Drerup, Justin, Liu, Yang, Hasty, Paul, Sharp, Zelton Dave, Curiel, Tyler J.
Publicado 2015

Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy

por Zhang, Deyi, Reyes, Ryan M., Osta, Erica, Kari, Suresh, Gupta, Harshita B., Padron, Alvaro S., Kornepati, Anand V. R., Kancharla, Aravind, Sun, Xiujie, Deng, Yilun, Wu, Bogang, Vadlamudi, Ratna, Li, Rong, Svatek, Robert S., Curiel, Tyler J.
Publicado 2021

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive th...

por Bai, Haiyan, Padron, Alvaro S, Deng, Yilun, Liao, Yiji J, Murray, Clare J, Ontiveros, Carlos, Kari, Suresh J, Kancharla, Aravind, Kornepati, Anand V R, Garcia, Myrna, Reyes, Ryan Michael, Gupta, Harshita B, Conejo-Garcia, Jose R, Curiel, Tyler
Publicado 2023

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

por Reyes, Ryan Michael, Deng, Yilun, Zhang, Deyi, Ji, Niannian, Mukherjee, Neelam, Wheeler, Karen, Gupta, Harshita B, Padron, Alvaro S, Kancharla, Aravind, Zhang, Chenghao, Garcia, Myrna, Kornepati, Anand V R, Boyman, Onur, Conejo-Garcia, Jose R, Svatek, Robert S, Curiel, Tyler J
Publicado 2021

Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues

por Padron, Alvaro Souto, Neto, Ruy Andrade Louzada, Pantaleão, Thiago Urgal, de Souza dos Santos, Maria Carolina, Araujo, Renata Lopes, de Andrade, Bruno Moulin, da Silva Leandro, Monique, de Castro, João Pedro Saar Werneck, Ferreira, Andrea Claudia Freitas, de Carvalho, Denise Pires
Publicado 2014